Deshpande D, Srivastava S, Gumbo T
Int J Antimicrob Agents. 2024; 64(3):107204.
PMID: 38754528
PMC: 11371482.
DOI: 10.1016/j.ijantimicag.2024.107204.
Gonzalo X, Drobniewski F
Antibiotics (Basel). 2022; 11(8).
PMID: 36009939
PMC: 9404707.
DOI: 10.3390/antibiotics11081070.
Gupta R, Al-Kharji N, Alqurafi M, Nguyen T, Chai W, Quan P
ACS Infect Dis. 2021; 7(8):2425-2436.
PMID: 34191496
PMC: 8369493.
DOI: 10.1021/acsinfecdis.1c00185.
Angula K, Legoabe L, Beteck R
Pharmaceuticals (Basel). 2021; 14(5).
PMID: 34068171
PMC: 8152995.
DOI: 10.3390/ph14050461.
Trigos A, Goudey B, Bedo J, Conway T, Faux N, Wyres K
mSphere. 2021; 6(3):e0024521.
PMID: 34047652
PMC: 8265638.
DOI: 10.1128/mSphere.00245-21.
Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
Fatima S, Bhaskar A, Dwivedi V
Front Immunol. 2021; 12:645485.
PMID: 33927718
PMC: 8076598.
DOI: 10.3389/fimmu.2021.645485.
Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution.
Gonzalo X, Satta G, Canseco J, McHugh T, Drobniewski F
BMC Microbiol. 2020; 20(1):271.
PMID: 32867678
PMC: 7457350.
DOI: 10.1186/s12866-020-01954-w.
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
Nahid P, Mase S, Migliori G, Sotgiu G, Bothamley G, Brozek J
Am J Respir Crit Care Med. 2019; 200(10):e93-e142.
PMID: 31729908
PMC: 6857485.
DOI: 10.1164/rccm.201909-1874ST.
Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant .
van Rijn S, Zuur M, Anthony R, Wilffert B, van Altena R, Akkerman O
Antimicrob Agents Chemother. 2018; 63(2).
PMID: 30455232
PMC: 6355583.
DOI: 10.1128/AAC.01489-18.
Tuberculosis elimination: where are we now?.
Matteelli A, Rendon A, Tiberi S, Al-Abri S, Voniatis C, Carvalho A
Eur Respir Rev. 2018; 27(148).
PMID: 29898905
PMC: 9488456.
DOI: 10.1183/16000617.0035-2018.
Tuberculosis series.
Silva D, Mello F, Kritski A, Dalcolmo M, Zumla A, Migliori G
J Bras Pneumol. 2018; 44(2):71-72.
PMID: 29791560
PMC: 6044651.
DOI: 10.1590/s1806-37562018000020001.
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
Silva D, Dalcolmo M, Tiberi S, Arbex M, Munoz-Torrico M, Duarte R
J Bras Pneumol. 2018; 44(2):153-160.
PMID: 29791557
PMC: 6044661.
DOI: 10.1590/s1806-37562017000000436.
Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis.
Sharma D, Dhuriya Y, Deo N, Bisht D
Front Microbiol. 2018; 8:2452.
PMID: 29321768
PMC: 5732208.
DOI: 10.3389/fmicb.2017.02452.
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
DAmbrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A
J Thorac Dis. 2017; 9(7):2093-2101.
PMID: 28840010
PMC: 5542985.
DOI: 10.21037/jtd.2017.06.16.
Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
van Rijn S, Srivastava S, Wessels M, van Soolingen D, Alffenaar J, Gumbo T
Antimicrob Agents Chemother. 2017; 61(9).
PMID: 28696238
PMC: 5571313.
DOI: 10.1128/AAC.02039-16.
Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
Cavanaugh J, Jou R, Wu M, Dalton T, Kurbatova E, Ershova J
J Antimicrob Chemother. 2017; 72(6):1678-1687.
PMID: 28333192
PMC: 5890777.
DOI: 10.1093/jac/dkx022.
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori G, Pontali E, Sotgiu G, Centis R, DAmbrosio L, Tiberi S
Int J Mol Sci. 2017; 18(2).
PMID: 28178199
PMC: 5343876.
DOI: 10.3390/ijms18020341.
Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
van Rijn S, Zuur M, van Altena R, Akkerman O, Proost J, de Lange W
Antimicrob Agents Chemother. 2017; 61(4).
PMID: 28137814
PMC: 5365678.
DOI: 10.1128/AAC.01783-16.
Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.
Rendon A, Tiberi S, Scardigli A, DAmbrosio L, Centis R, Caminero J
J Thorac Dis. 2016; 8(10):2666-2671.
PMID: 27867538
PMC: 5107456.
DOI: 10.21037/jtd.2016.10.14.
Recent developments in the diagnosis and management of tuberculosis.
Sulis G, Centis R, Sotgiu G, DAmbrosio L, Pontali E, Spanevello A
NPJ Prim Care Respir Med. 2016; 26:16078.
PMID: 27808163
PMC: 5093435.
DOI: 10.1038/npjpcrm.2016.78.
